China’s Sinovac begins late stage preliminaries for its COVID-19 antibody Kumar Jeetendra | July 7, 2020 China’s Sinovac Biotech is starting Phase III trials of its potential coronavirus vaccine in Brazil, ” said on Monday, becoming among three companies to transfer to the late stages at the race to develop an inoculation against the disorder. It follows a fast-track approval for the trials by Brazilian labs last week. Sinovac stated the …
90 Percent of China’s Sinovac Workers, Households took coronavirus vaccine, says CEO Kumar Jeetendra | September 7, 2020 Approximately 90 percent of Sinovac Biotech Ltd employees and their families have obtained an experimental coronavirus vaccine developed by the Chinese company under the nation’s emergency usage programme, its chief executive said on Sunday. The extent of inoculations under the emergency programme, which China launched in July but has released few details about, points to …
China’s Sinovac is sheltered, says Brazil’s leading research organization Kumar Jeetendra | October 20, 2020 São Paulo’s Butantan Institute, one of Brazil’s leading biomedical research centers, which is carrying out the Stage 3 tests, said the two-dose vaccine, called CoronaVac, was secure in a trial thus far involving 9,000 volunteers. But Butantan manager Dimas Covas said data on how effective the vaccine is will not be published until the trial …
Sinovac Biotech has secured $515 million in financing from a local company to double manufacturing capacity of its corona vaccine Kumar Jeetendra | December 7, 2020 China’s Sinovac Biotech has secured $515 million in financing from a local company to double manufacturing capacity of its coronavirus vaccine, the companies said on Monday, as it anticipates efficacy data of its experimental shot this month. The investment deal also comes as Sinovac expands provide deals and trials of its experimental COVID-19 vaccine CoronaVac …
EMA opens audit of China’s Sinovac Covid jab Kumar Jeetendra | May 4, 2021 The European Medicines Agency said Tuesday it has started a “rolling review” of China’s Sinovac coronavirus jab, a process that could lead to eventual approval for the European market. Made by Sinovac’s Beijing-based Life Sciences unit, the vaccine contains an inactivated coronavirus that cannot cause a disease, but helps a person to develop antibodies against …
